CEL-SCI CORPORATION Operating Lease Liability
CEL-SCI CORPORATION (CVM) had Operating Lease Liability of $1.63 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-14
- 2026-06-30: Operating Lease, Liability $1.63M.
- 2026-03-31: Operating Lease, Liability $1.66M.
- 2025-12-31: Operating Lease, Liability $1.69M.
- 2025-09-30: Operating Lease, Liability $1.43M.
| Period end | Operating Lease, Liability | Operating Lease, Liability as first filed |
|---|---|---|
| 2026-06-30 | $1.63M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $1.66M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $1.69M 10-Q · filed 2026-02-17 | |
| 2025-09-30 | $1.43M 10-K · filed 2025-12-29 | |
| 2025-06-30 | $1.49M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $1.54M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $1.60M 10-Q · filed 2025-02-14 | |
| 2024-09-30 | $1.65M 10-K · filed 2025-01-13 | |
| 2024-06-30 | $1.71M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $1.75M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $1.80M 10-Q · filed 2024-02-14 | |
| 2023-06-30 | $1.90M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $190.00K 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $2.00M 10-Q · filed 2023-02-14 | |
| 2022-09-30 | $2.00M 10-Q · filed 2023-08-10 | $200.00K 10-Q · filed 2023-05-12 |
| 2022-06-30 | $2.10M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $2.10M 10-Q · filed 2022-05-13 | |
| 2021-06-30 | $1.10M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $1.20M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $1.20M 10-Q · filed 2021-02-12 | |
| 2020-09-30 | $1.30M 10-Q · filed 2021-08-13 | $1.20M 10-K · filed 2020-12-29 |
| 2020-06-30 | $1.30M 10-Q/A · filed 2020-12-31 | |
| 2020-03-31 | $900.00K 10-Q/A · filed 2020-12-30 | |
| 2019-09-30 | $1.30M 10-Q · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |